Conference Day 2 (5/11/25)Wednesday, 5 November 2025 - Amsterdam CET

Mesenchymal Stromal Cells have great regenerative potential and their EV reflect this potential

Consistent and scalable manufacturing has been one of the main challenges so far

With EVscale™ we have developed a technology platform overcoming manufacturing challenges and enabling access to large amounts of EV with consistent biological activity

In this presentation we will show our in vitro and in vivo study results for two main indications Phoenestra is currently moving towards proof-of-concept

EVerZom is a French biopharmaceutical company spun out from CNRS and Université Paris Cité, specializing in the development of bioprocesses and therapeutic applications based on exosomes — extracellular vesicles naturally secreted by cells, with regenerative, immunomodulatory, and drug delivery potential. The company has developed a unique, fully integrated, and patented technological platform enabling industrial-scale production, functional engineering, and advanced characterization of exosomes.

At the core of this platform lies a mechanical stimulation technology based on fluid shear stress calibrated to the Kolmogorov length scale, which triggers massive exosome release while maintaining vesicle integrity and functionality. This proprietary method, validated in 10L bioreactors under GMP conditions in collaboration with the French Blood Establishment (EFS), achieves yields up to 100x higher than conventional methods, making it suitable for clinical-grade manufacturing.

The company’s lead therapeutic program, EVerGel™, is a thermosensitive hydrogel embedding MSC-derived exosomes for tissue regeneration in the gastrointestinal tract, with a focus on the treatment of complex digestive fistulas in patients with Crohn’s disease. Upon injection, the formulation transitions into a gel at body temperature, enabling localized and sustained delivery. The exosomes exert synergistic effects by promoting tissue repair, reducing inflammation, and modulating immune responses. EVerGel has shown strong efficacy in eight preclinical animal models, with regulatory toxicology studies scheduled for 2025 and first-in-human clinical trials planned for 2026 (Phase I/IIa).

• Market readiness assessment and go-to-market strategy for exosome-based therapeutics and diagnostics
• Translating R&D excellence into regulatory and commercial milestones
• Building investment narratives for scalable manufacturing and quality assurance
• Strategic partnership models to accelerate industrial adoption

• Experiences and lessons from the journey through pre-clinical to clinical
• Practical strategies and approaches on:
  • Manufacturing scale-up
  • GMP Compliance
  • Specific clinical trail design considerations for exosomes
• Overcoming unexpected challenges and adapting development strategies.

• Bridging the gap between academic discovery and industrial/commercial requirements
• Leveraging CDMO expertise for process development, manufacturing, and tech transfer
• Models for successful collaboration to accelerate development
• Overcoming intellectual property and communication challenges in partnerships
• From Discovery to Investment Readiness
  • Prioritizing Research and Building Strategic Bridges in the Exosome and ATMP Landscape.

Spotlight Presentation – Calling all Technology Thought Leaders!

Whether you're increasing your company profile, launching a new product or focusing on new business development opportunities, collaborate with us to identify custom solutions to help you reach your goals.

Contact us today to learn more: Partners@informaconnectls.com

Table Topics:

• Regulation
• Investment Landscape
• Novel Applications

Facilitated small group discussions:

• Identify actionable strategies and insights
• Share key takeaways and future predictions